EU panel backs AstraZeneca hypertension drug baxdrostat

BRUSSELS: AstraZeneca said on Friday a European medicines committee had backed its hypertension pill baxdrostat, branded as Baxfendy, for marketing authorization, potentially making it the first drug of its class to reach patients in the European Union. The Committee for Medicinal Products for Human Use, or CHMP, ⁠recommended baxdrostat for ⁠adults whose hypertension is insufficiently controlled by at least two medicines. If approved, Baxfendy would be the EU’s first and only aldosterone synt

NewsBeagle is a discovery engine. We show the headline, a short source-supplied summary and clear attribution. The complete reporting remains with the publisher.